Compare Liquidia Corp. with Similar Stocks
Dashboard
1
With a growth in Operating Profit of 460.03%, the company declared Very Positive results in Sep 25
- The company has declared positive results in Jan 70 after 8 consecutive negative quarters
- RAW MATERIAL COST(Y) Fallen by -62.97% (YoY)
- NET SALES(Q) Highest at USD 54.34 MM
- OPERATING PROFIT(Q) Highest at USD 2.24 MM
2
Risky -
3
Rising Promoter Confidence
4
Market Beating performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
USD 3,146 Million (Small Cap)
NA (Loss Making)
NA
0.00%
1.61
-552.55%
142.65
Revenue and Profits:
Net Sales:
92 Million
(Quarterly Results - Dec 2025)
Net Profit:
15 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
8.14%
0%
8.14%
6 Months
47.59%
0%
47.59%
1 Year
147.01%
0%
147.01%
2 Years
134.0%
0%
134.0%
3 Years
404.29%
0%
404.29%
4 Years
409.94%
0%
409.94%
5 Years
1214.44%
0%
1214.44%
Liquidia Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
134.04%
EBIT Growth (5y)
-34.31%
EBIT to Interest (avg)
-24.13
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.33
Sales to Capital Employed (avg)
0.22
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
85.52%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
142.65
EV to EBIT
-29.66
EV to EBITDA
-30.14
EV to Capital Employed
55.34
EV to Sales
45.96
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-186.62%
ROE (Latest)
-552.55%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 42 Schemes (13.74%)
Foreign Institutions
Held by 73 Foreign Institutions (3.85%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
92.00
54.30
69.43%
Operating Profit (PBDIT) excl Other Income
20.10
2.20
813.64%
Interest
6.90
6.90
Exceptional Items
0.00
0.00
Consolidate Net Profit
14.60
-3.50
517.14%
Operating Profit Margin (Excl OI)
215.00%
32.50%
18.25%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 69.43% vs 517.05% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is 517.14% vs 91.59% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
158.30
14.00
1,030.71%
Operating Profit (PBDIT) excl Other Income
-49.80
-119.10
58.19%
Interest
24.20
14.70
64.63%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-68.90
-128.30
46.30%
Operating Profit Margin (Excl OI)
-324.50%
-8,666.30%
834.18%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 1,030.71% vs -20.00% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 46.30% vs -63.44% in Dec 2024
About Liquidia Corp. 
Liquidia Corp.
Pharmaceuticals & Biotechnology
Liquidia Corp operates through it's subsidiaries, Liquidia Technologies, Inc. and RareGen, LLC (RareGen). The Company, through Liquidia Technologies, Inc., is a late-stage clinical biopharmaceutical company focused on the development and commercialization of products using it's PRINT technology. It is focused on developing two product candidates: LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and LIQ865, an injectable, sustained-release formulation of bupivacaine for the management of local post-operative pain for three to five days after a procedure. RareGen provides commercialization for rare disease pharmaceutical products, such as generic Remodulin (treprostinil) for pulmonary arterial hypertension. Treprostinil can be administered as a continuous infusion through the use of an infusion pump or continuous intravenous infusion through the use of a central venous catheter.






